Vascular calcification (VC) is associated with increased cardiovascular event rates, particularly in patients with end-stage kidney disease (ESKD). Dysregulated mineral metabolism and inflammation have been shown to promote VC, however, treatment options targeting VC specifically are not available. This review outlines the pathophysiological mechanisms contributing to VC in ESKD and describes recent studies evaluating the effects of the first-in-class inhibitor of VC, SNF472.

中文翻译：

---

SNF472：作用机制和临床试验结果。

血管钙化 (VC) 与心血管事件发生率增加有关，尤其是在终末期肾病 (ESKD) 患者中。失调的矿物质代谢和炎症已被证明会促进 VC，但是，没有专门针对 VC 的治疗方案。这篇综述概述了 ESKD 中 VC 的病理生理机制，并描述了最近评估 VC 的一流抑制剂 SNF472 的作用的研究。